duligotuzumabAgricultural BiotechnologyUpdated on Apr 8, 2020 View more like this | Visit SHIRLEY, NY | Contact Bella Smith |

Fayette, J., Wirth, L., Oprean, C., Udrea, A., Jimeno, A., Rischin, D.,... & O’Brien, P. (2016). Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in squamous cell carcinoma of the head and neck (MEHGAN Study). Frontiers in oncology, 6, 232.